PMV Pharmaceuticals filings document a clinical-stage precision oncology company focused on small molecule therapies targeting p53. The company’s Form 8-K reports disclose operating results, financial condition updates, Regulation FD materials, and rezatapopt clinical disclosures from the PYNNACLE study in tumors with a TP53 Y220C mutation.
Proxy materials describe annual meeting matters, board composition, stockholder voting procedures, and governance practices. The filing record also identifies PMV’s Nasdaq-listed common stock and includes risk and forward-looking-statement disclosures tied to drug development, regulatory pathways, capital resources, and clinical-stage biotechnology operations.
PMV Pharmaceuticals, Inc. (PMVP) is reported to have a significant shareholder group led by Samsara BioCapital entities and Srinivas Akkaraju. The reporting persons disclose beneficial ownership of 7,577,467 shares of common stock, representing 9.99% of PMV’s outstanding common stock.
The holdings include, for each of Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P., 3,620,000 common shares, Pre-Funded Warrants exercisable for up to 3,400,000 shares, and Common Warrants exercisable for up to 7,020,000 shares. All percentages are calculated using 53,458,058 shares outstanding as of August 14, 2026 plus 22,055,000 shares issued in PMV’s September 2, 2026 equity offering and Warrants exercisable within 60 days.
Each Warrant contains a Beneficial Ownership Blocker that prevents exercises which would cause the holder and its affiliates to own more than 9.99% of PMV’s common stock, limiting further Warrant exercise above 7,577,467 shares currently attributed to the reporting group.
PMV Pharmaceuticals, Inc. (PMVP) priced an underwritten public offering of (i) 22,055,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 19,900,000 shares, and (ii) accompanying warrants to purchase 41,955,000 shares of common stock. Each share plus accompanying warrant is priced at $1.21, and each pre-funded warrant plus accompanying warrant at $1.20999, reflecting a $0.00001 pre-funded warrant exercise price. The company expects gross proceeds of about $50.8 million and net proceeds of about $47.0 million, and plans to use them, together with existing cash, primarily to fund late-stage clinical development, regulatory submission and commercialization preparation for rezatapopt. Based on its current plan, PMV believes this financing, together with existing cash, will fund operations into the first quarter of 2028. The accompanying warrants are immediately exercisable at $1.21 per share for five years and include a reset mechanism and potential Mandatory Exercise tied to FDA acceptance of the company’s NDA for rezatapopt.
PMV Pharmaceuticals, Inc. (PMVP) is conducting a primary offering of 22,055,000 shares of common stock and pre-funded warrants for 19,900,000 shares, each sold with a common stock warrant, for total gross proceeds of $50.8 million at approximately $1.21 per unit. The offering also registers 41,955,000 common stock warrants, immediately exercisable for five years at an initial exercise price of $1.21 per share, with price and share-count adjustments tied to FDA acceptance of an NDA for rezatapopt.
PMV estimates net proceeds of about $47.0 million after fees and expenses, on top of $79.4 million in cash and equivalents as of June 30, 2026, and expects this liquidity to fund operations into the first quarter of 2028. Proceeds are earmarked primarily for late-stage development, regulatory submission and commercialization preparation for lead candidate rezatapopt in TP53 Y220C–mutant ovarian cancer.
PMV Pharmaceuticals, Inc. (PMVP) is updating its previously filed at-the-market equity program. The company had registered the offer and sale of its common stock under an Open Market Sale Agreement with Jefferies LLC, permitting issuances of shares with an aggregate offering price of up to $113,792,846.40 from time to time. This supplement terminates the company’s continuous offering under that ATM prospectus supplement, and PMV Pharmaceuticals states that no shares of common stock were sold under the program. The termination does not otherwise change the underlying sales agreement or the parties’ rights and obligations under it.
PMV Pharmaceuticals, Inc. (PMVP) is conducting a takedown under its Form S-3 shelf to offer common stock, pre-funded warrants and accompanying common stock warrants. Each share or pre-funded warrant is sold together with a common stock warrant, and this supplement also covers the shares issuable on exercise of those warrants.
The common stock warrants are immediately exercisable, expire in 2031 and have an exercise price that can reset downward after an FDA decision to accept PMV’s planned New Drug Application for rezatapopt in TP53 Y220C platinum‑resistant/refractory ovarian cancer, with a corresponding increase in warrant share count to keep the aggregate exercise price constant. Under certain positive NDA‑acceptance outcomes, PMV may require holders to exercise up to 50% of their warrants for cash, with unexercised portions lapsing.
PMV plans to seek accelerated approval for rezatapopt and expects to submit an NDA in the first quarter of 2027. Net proceeds, together with existing cash, will fund late‑stage development, regulatory submission and commercialization preparation for rezatapopt, plus working capital and general corporate purposes. As of June 30, 2026, PMV had cash, cash equivalents and restricted cash of $79.4 million, net tangible book value of $71.5 million, or $1.34 per share based on 53,460,432 shares outstanding, while the last reported Nasdaq Global Select Market sale price on August 28, 2026 was $1.22 per share.
PMV Pharmaceuticals, Inc. (PMVP) reported updated interim ovarian cancer data from the Phase 2 pivotal portion of its registrational PYNNACLE trial of rezatapopt monotherapy in TP53 Y220C advanced solid tumors. The trial uses a 2000 mg once-daily oral dose and includes platinum-resistant/refractory ovarian cancer patients, for whom enrollment for the primary analysis has been completed.
As of a May 14, 2026 data cutoff, rezatapopt continued to show a favorable and consistent safety and tolerability profile across cohorts, with mostly Grade 1–2 treatment-related adverse events and a 5% discontinuation rate due to treatment-related events; the ovarian cancer cohort safety profile was similar to the overall population. PMV Pharma received FDA feedback that continues to support its strategy to seek accelerated approval for rezatapopt in platinum-resistant/refractory TP53 Y220C ovarian cancer based on the Phase 2 portion of PYNNACLE and anticipates submitting a New Drug Application in the first quarter of 2027. The company plans to present updated data from all Phase 2 pivotal cohorts, including primary analysis data from the ovarian cohort, at a medical conference in the fourth quarter of 2026.
PMV Pharmaceuticals, Inc. reported continued operating losses for the quarter and six months ended June 30, 2026 while advancing its lead oncology candidate, rezatapopt. Net loss was $18.1 million for the quarter and $36.1 million for the first half of 2026. Cash, cash equivalents, and marketable securities totaled $79.4 million at June 30, 2026, with management estimating this will fund planned operations only through the second quarter of 2027 and disclosing substantial doubt about its ability to continue as a going concern.
Research and development expenses were $30.0 million for the first half, primarily related to rezatapopt and the Phase 2 pivotal PYNNACLE trial. The FDA granted Orphan Drug Designation in March 2026 for rezatapopt in TP53 Y220C positive ovarian, fallopian tube, and primary peritoneal cancers, and enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis has been completed. The company plans to seek accelerated approval with an initial NDA submission targeted for the first quarter of 2027.
PMV Pharmaceuticals reported second quarter 2026 results and a key clinical milestone for its lead asset rezatapopt. Enrollment for the primary analysis of platinum-resistant/refractory ovarian cancer patients in the Phase 2 monotherapy portion of the registrational PYNNACLE trial has been completed. The company plans to submit a New Drug Application for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027 and notes existing Fast Track and Orphan Drug Designations.
PMV Pharma had $79.4 million in cash, cash equivalents and marketable securities as of June 30, 2026, and expects this to fund operations through the second quarter of 2027. For the quarter, net loss was $18.1 million versus $21.2 million a year earlier, driven mainly by lower contract research organization and finance support costs. Research and development expenses were $14.7 million compared with $18.4 million, and general and administrative expenses were $4.2 million compared with $4.5 million, reflecting cost reductions as the company advances its precision oncology pipeline targeting TP53 Y220C mutations.
Sio Capital Management, LLC, a Delaware investment adviser, reports beneficial ownership of 2,634,137 shares of PMV Pharmaceuticals, Inc. common stock as of June 30, 2026. This represents 4.94% of the class, based on 53,331,766 shares of common stock outstanding as of May 12, 2026.
Sio has shared voting and dispositive power over all 2,634,137 shares and no sole voting or dispositive power. The shares are held by various client funds for which Sio is investment adviser, with oversight by Sio GP, LLC, and control relationships involving Michael Castor, whose beneficial ownership is expressly disclaimed.
Item 5 states that the reporting person’s holdings constitute 5 percent or less of the issuer’s outstanding common stock.
ArrowMark Colorado Holdings, LLC reports beneficial ownership of 1,959,579 shares of PMV Pharmaceuticals, Inc. common stock, representing 3.67% of the class as of 06/30/2026.
The filing amends a Schedule 13G and states ArrowMark has sole voting and sole dispositive power over all 1,959,579 shares.